Skip to main content
. Author manuscript; available in PMC: 2011 Sep 24.
Published in final edited form as: Vaccine. 2010 Aug 13;28(41):6675–6683. doi: 10.1016/j.vaccine.2010.08.012

FIGURE 6.

FIGURE 6

Strong antigen-specific CD8 T cells responses were elicited by DC-directed IDLVs for in vivo delivery of the melanoma antigen hgp100 or HIV-1 subtype B gag. (A). Each of the two naïve C57BL/6 mice received 1048 ng p24 of the DC-directed IDLV encoding the melanoma antigen hgp100 (denoted as FUW-hgp100/SVGmu(IN−)) through a footpad injection. A mouse receiving no immunization (No LV) was included as a negative control. At 3 weeks post-immunization, splenocytes were analyzed by tetramer staining (upper) and intracellular staining (lower). (B). Each of the two naïve Balb/c mice were administered 16200 ng p24 of the DC-directed IDLV encoding HIV-1 gag (denoted as FUW-gag/SVGmu(IN−)) through the footpad route. A mouse receiving no immunization (No LV) was included as a negative control. At 3 weeks post-immunization, splenocytes were analyzed by tetramer staining (upper) and intracellular staining (lower).